Business Wire

Rigaku Announces STAvesta, a Thermal Analyzer Tailor-made for Next-generation Material Development

8.7.2025 16:00:00 CEST | Business Wire | Press Release

Share

Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) has launched worldwide sales of STAvesta, a thermal analyzer that simultaneously measures a sample’s weight and change in calorific value during heating. STAvesta responds to needs in a wide array of fields where thermal analysis is required. It is expected to find use in a wide variety of material-analysis applications for the development of advanced features and complex materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708207135/en/

STAvesta

FlatBlank, a Revolutionary Auto-adjustment Feature, Dramatically Reduces Workload
In conventional thermal analysis, baseline adjustment must be performed by hand before measurement can begin. This process can be time-consuming and frustrating, particularly for novice users. Rigaku’s newly developed FlatBlank, a baseline auto-adjustment feature, automates this process, dramatically reducing waiting time associated with the process. Measurement can begin as soon as preparations are ready, enabling smooth setup after sample insertion and improving work efficiency overall. The benefits are particularly pronounced in workplaces conducting R&D handling multiple samples.

Key Features of STAvesta

  • Broad support for a wide range of users
    STAvesta easily switches among seven types of electric furnace1 according to purpose and measurement conditions. A real-time imaging feature enables samples to be observed during measurement, contributing to improved speed and accuracy in R&D.
    1. Six types of electric furnace in some sales countries.
  • Vestaeye, a new, world-first feature, provides self-diagnosis for constant monitoring of device status.
    Before and during measurement, the device monitors itself constantly for signs of abnormality. Users can confirm at a glance whether the device is functioning correctly before starting measurement, so waste of precious samples is eliminated.
  • Next-generation thermal analysis features for outstanding temperature-control performance
    In thermal analysis, when a temperature is set for a sample, the sample may fail to heat up to that setting or may heat up above that setting, precluding accurate measurement. Rigaku’s new temperature control feature dramatically reduces this problem of incorrect temperature. Samples are heated to and held at the required temperature in strict accordance with the preset temperature program. As a result, researchers can easily obtain the intended reactions and obtain stable measurement.
  • Rapid processing of up to 52 samples in a compact device
    STAvesta’s automatic sample changer dramatically increases the number of samples that can be handled from 28 in the previous model to 52. With 2.3 times the transport speed of the previous model and support for up to 1,000 continuous measurements, STAvesta achieves superb measurement efficiency. The tray section supports gas flow, making it ideal for measurement of powders that are prone to moisture absorption. STAvesta is designed so that attachment of the automatic sample changer does not increase its footprint, assuring industry-leading space-saving performance.

Kiyoshi Ogata, Senior Executive Vice President and General Manager of the Product Division, offered the following comment:
Our aim in developing STAvesta was to create a new standard in thermal analyzer. The device incorporates not only improved operability but also support features such as self-diagnostic features for failure detection, so users can use it with confidence. Measurement features are also dramatically strengthened. The device is packed with advanced technologies, such as a structure that rapidly reduces oxygen concentration to support metallic and inorganic samples that are prone to oxidation. In short, this revolutionary thermal analyzer achieves both efficiency and reliability in the R&D workspace.

In launching this product, Rigaku is entering a new market in earnest, drawing on the trust and track record it has accumulated over many years. Leveraging its solid operating base in Japan, Rigaku aims to establish a firm and strong presence in global markets.

Learn more about STAvesta
URL: https://rigaku.com/products/thermal-analysis/sta/stavesta?setLang=english

About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com/english

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708207135/en/

Contacts

Press Contact:
Sawa Himeno
Head of Communications Dept., Rigaku Holdings Corporation
prad@rigaku.co.jp
Tel: +81 90 6331 9843

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye